This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sun gets judgment against US states' antitrust claims over Methylphenidate, Phenytoin

( April 16, 2026, 20:06 GMT | Official Statement) -- MLex Summary: A Connecticut federal judge granted summary judgement in favor of Sun Pharmaceutical against state plaintiffs' US antitrust claims over the pricing of the drugs Methylphenidate and Phenytoin. District Judge Michael P. Shea found that the states’ body of evidence does not tend to exclude the possibility that Sun acted independently in raising its Phenytoin contract prices and does not permit a reasonable inference that Sun’s decision to enter the Methylphenidate market and match its competitors’ prices was more likely than not the product of Sun’s participation in a conspiracy.See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections